Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 30.03.2026 3 BMC Cancer 1 Br J Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 1 Clin Cancer Res 1 Eur J Radiol 1 Int J Radiat Oncol Biol Phys 1 J Nucl Med 1 J Urol 1 N Engl J Med 1 Oncogene 2 PLoS One 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. SODERKVIST K, Zia M, Gunnlaugsson A, Josefsson A, et al
   Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15906.
   PubMed         Abstract available
   
   
2. DEMARK-WAHNEFRIED W, Rogers LQ, Zubkoff L, Pisu M, et al
   Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15851.
   PubMed        
   
   
3. WANG H, Rajagopal A, Cao K, Cimolai K, et al
   Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.
   BMC Cancer. 2026 Mar 26. doi: 10.1186/s12885-026-15854.
   PubMed        
   
   

   
   Br J Cancer

4. CRABB SJ, Morgan A, Stefanopoulou E, Fleure L, et al
   Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial.
   Br J Cancer. 2026 Mar 24. doi: 10.1038/s41416-026-03375.
   PubMed         Abstract available
   
   

   
   Cancer

5. VAN TUIJL LA, Pan KY, Basten M, Vermeulen R, et al
   Psychosocial factors and the risk of cancer: An individual-participant data meta-analysis.
   Cancer. 2026;132:e70271.
   PubMed         Abstract available
   
   

   
   Cancer Lett

6. YAN H, Mao AW, Li D, Fu G, et al
   AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors.
   Cancer Lett. 2026 Mar 24:218447. doi: 10.1016/j.canlet.2026.218447.
   PubMed         Abstract available
   
   

   
   Cancer Res

7. APOSTOLOV E, Roden DL, Holliday H, Cazet A, et al
   Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy-Naive Localized Prostate Cancer.
   Cancer Res. 2026 Mar 25:OF1-OF18. doi: 10.1158/0008-5472.CAN-25-1202.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

8. ANTONARAKIS ES, Cao Q, Catharine V, Carneiro BA, et al
   Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study.
   Clin Cancer Res. 2026 Mar 25. doi: 10.1158/1078-0432.CCR-25-4823.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

9. WIBULPOLPRASERT P, Bihan DL, Leelarujijaroen P, Kampaengtip A, et al
   Potential of the signature index (S-index), a diffusion MRI Biomarker, to enhance diagnosis of clinically significant prostate cancer and decrease the rate of unnecessary biopsies.
   Eur J Radiol. 2026;199:112788.
   PubMed         Abstract available
   
   

   
   Int J Radiat Oncol Biol Phys

10. ANGER E, Supiot S, Josset Q, Pasquier D, et al
    Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.
    Int J Radiat Oncol Biol Phys. 2026 Mar 19:S0360-3016(26)00502.
    PubMed         Abstract available
    
    

    
    J Nucl Med

11. HOANG TT, Bauer D, Ingham A, Miranda IC, et al
    Delta-like Ligand 3-Directed (225)Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models.
    J Nucl Med. 2026 Mar 26:jnumed.125.271302. doi: 10.2967/jnumed.125.271302.
    PubMed         Abstract available
    
    

    
    J Urol

12. SCHNAUSS M, Handa N, Nateghi R, Alam R, et al
    Clinical and Reader Associated Correlates of Clinically Significant MRI-Invisible Prostate Cancer based on Negative MRI.
    J Urol. 2026 Mar 23:101097JU0000000000005028. doi: 10.1097/JU.0000000000005028.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. LANGLEY RE, Gilbert DC, Mangar S, Rosen S, et al
    Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.
    N Engl J Med. 2026 Mar 25. doi: 10.1056/NEJMoa2511781.
    PubMed         Abstract available
    
    

    
    Oncogene

14. CHEN CH, Brown R, Vander Griend DJ, Gao AC, et al
    Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.
    Oncogene. 2026 Mar 23. doi: 10.1038/s41388-026-03723.
    PubMed         Abstract available
    
    

    
    PLoS One

15. PAPACHRISTOS MG, Spezi E, Fuentes C, Evangelou I, et al
    Prostate cancer tissue mapping and stratification using DRAQ5 and Eosin fluorescent labels integrated with AI classification and segmentation algorithms.
    PLoS One. 2026;21:e0345014.
    PubMed         Abstract available
    
    
16. XU K, Zhou S, Chen Y, Chen J, et al
    LM-UNet: Lightweight Mamba-UNet Prostate MRI image segmentation network.
    PLoS One. 2026;21:e0339719.
    PubMed         Abstract available
    
    

    
    Urology

17. BRADLEY MASON J, Tallman J
    Editorial Comment on "Patient-Reported Psychological and Prostate Cancer-Specific Functional Outcomes Among Men With Low-Risk Prostate Cancer Two Years After Diagnosis: The PREPARE Prospective Cohort Study".
    Urology. 2026 Mar 24:S0090-4295(26)00211-6. doi: 10.1016/j.urology.2026.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum